Adamas Pharmaceuticals (NASDAQ:ADMS) was downgraded by investment analysts at ValuEngine from a “hold” rating to a “sell” rating in a note issued to investors on Monday, February 4th.
Other analysts have also issued research reports about the company. HC Wainwright reaffirmed a “buy” rating and issued a $40.00 price target on shares of Adamas Pharmaceuticals in a research note on Monday, November 5th. Cowen set a $30.00 price target on Adamas Pharmaceuticals and gave the company a “buy” rating in a research note on Thursday, November 1st. Zacks Investment Research upgraded Adamas Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Friday, February 1st. Mizuho reiterated a “hold” rating and issued a $11.00 price objective on shares of Adamas Pharmaceuticals in a research report on Friday, January 11th. Finally, Leerink Swann initiated coverage on Adamas Pharmaceuticals in a research report on Monday, November 12th. They issued an “outperform” rating and a $20.00 price objective for the company. Two equities research analysts have rated the stock with a sell rating, three have issued a hold rating and four have assigned a buy rating to the company’s stock. Adamas Pharmaceuticals currently has an average rating of “Hold” and an average price target of $30.00.
Shares of NASDAQ:ADMS traded up $0.61 during trading on Monday, hitting $11.80. 508,252 shares of the stock were exchanged, compared to its average volume of 462,741. The company has a current ratio of 8.95, a quick ratio of 8.74 and a debt-to-equity ratio of 1.01. The firm has a market capitalization of $303.70 million, a PE ratio of -2.97 and a beta of 1.41. Adamas Pharmaceuticals has a 1-year low of $7.42 and a 1-year high of $32.90.
Hedge funds have recently added to or reduced their stakes in the company. Millennium Management LLC raised its position in shares of Adamas Pharmaceuticals by 318.2% during the second quarter. Millennium Management LLC now owns 342,180 shares of the specialty pharmaceutical company’s stock worth $8,839,000 after acquiring an additional 260,360 shares during the last quarter. MetLife Investment Advisors LLC raised its position in shares of Adamas Pharmaceuticals by 55.2% during the third quarter. MetLife Investment Advisors LLC now owns 16,709 shares of the specialty pharmaceutical company’s stock worth $335,000 after acquiring an additional 5,940 shares during the last quarter. Fosun International Ltd bought a new stake in Adamas Pharmaceuticals in the third quarter valued at about $1,152,000. Teachers Advisors LLC increased its holdings in Adamas Pharmaceuticals by 68.7% in the third quarter. Teachers Advisors LLC now owns 61,024 shares of the specialty pharmaceutical company’s stock valued at $1,222,000 after purchasing an additional 24,859 shares during the last quarter. Finally, BlackRock Inc. increased its holdings in Adamas Pharmaceuticals by 2.4% in the third quarter. BlackRock Inc. now owns 1,889,914 shares of the specialty pharmaceutical company’s stock valued at $37,836,000 after purchasing an additional 43,818 shares during the last quarter. Institutional investors own 79.76% of the company’s stock.
Adamas Pharmaceuticals Company Profile
Adamas Pharmaceuticals, Inc discovers, develops, and sells therapies for chronic neurologic disorders. The company's approved/commercial product is GOCOVRI, an amantadine therapy for the treatment of levodopa-induced dyskinesia in patients with Parkinson's disease. Its partnered approved/commercial products include Namzaric (memantine hydrochloride extended-release and donepezil hydrochloride) capsules; and Namenda XR (memantine hydrochloride) extended release capsules for the treatment of moderate to severe Alzheimer's disease.
See Also: The Structure of a Futures Contract
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Adamas Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamas Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.